About bsbh

This author has not yet filled in any details.
So far bsbh has created 224 blog entries.

Webinar: COVID-19 VACCINES ARE COMING – A Magic Bullet or a Load of Blanks?

Wednesday, 30 September, 20.00 – 21.00 CET (2.00 pm – 3.00 pm, US Eastern)

Given the huge societal and economic impacts of the coronavirus in Europe, everyone is hopeful that COVID-19 vaccines will soon be available – but what happens next? According to an Economist report from August 2018, in the past decade vaccination rates in some European countries have often fallen below those in parts of Africa. It claims that Italy, France and Serbia have lower child-vaccination rates than Burundi, Rwanda and Senegal. After billions of Euros have been invested by governments, what will happen if many EU citizens are unwilling to take the vaccine? What can be done now to ensure that those who need the COVID-19 vaccine most are treated first when the vaccines are available? Furthermore, how do EU member states plan on measuring and monitoring the safety of vaccines that have been rapidly put onto the market ̶ and who will ultimately be accountable? And from the patient’s perspective, how can we build trust around the EU’s management of COVID-19, which has become increasingly politicised?

Register
Webinar: COVID-19 VACCINES ARE COMING – A Magic Bullet or a Load of Blanks?2020-09-28T08:09:58+00:00

EHDEN Webinar #3

IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ Webinar #3: What could the pharma industry look like by 2030 – digital discovery, R&D and post-authorisation? 28 October, 15h30-16h30 CET REGISTER [...]

EHDEN Webinar #32020-09-17T08:51:55+00:00

EHDEN Webinar #2

IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ Webinar #2: Determining value for patients and harnessing RWE 22 October 14-15h CET REGISTER [...]

EHDEN Webinar #22020-09-16T15:04:42+00:00

EHDEN Online Roadshow

A series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’

Goal of the webinar series:
The webinars will present an opportunity to explore utilisation of Real World Data/Real World Evidence in Spain and Spanish-speaking countries, as well as to compare and analyse wider European and Spanish RWD/RWE initiatives in the spirit of creating collaborations and strengthening relationships.

More info & Registration
EHDEN Online Roadshow2020-09-17T12:13:10+00:00

EHDEN: The Role of Health Data in the Post Covid-19 Era

IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ Webinar #1: The need for health data in the era of Covid-19 9 October, 14.30-15.30 CET REGISTER [...]

EHDEN: The Role of Health Data in the Post Covid-19 Era2020-09-16T14:34:52+00:00

Who pays for hope? – treating cancer early

9 September, 2020, 8.30 CET

Cancer is still often considered a death sentence. It is the second leading cause of death globally and will soon overtake cardiovascular disease as the number one killer. As a result, the main effect that people expect treatments to have is to prolong overall survival either through curing the disease or by slowing its progression and reducing cancer-related symptoms. Indeed, great progress has been made in recent years and cancer mortality grows at a much slower pace than cancer incidence.

This webinar intends to discuss different perspectives on how funding decisions should be approached depending on the setting of the disease.

Watch video
Who pays for hope? – treating cancer early2020-09-22T10:41:29+00:00

Webinar: Lung Cancer in Europe: New Ideas for Policy Action

15 July, 15.00-16.00 CET

This year more than half a million Europeans will be diagnosed with lung cancer. While many countries have improved the management of lung cancer through better prevention, detection, diagnosis and treatment, the disease continues to claim 1 in 5 cancer deaths across Europe, posing significant challenges to patients and healthcare systems. To identify further opportunities for improvement, The Economist Intelligence Unit made a comparative analysis of lung cancer policies across 27 countries. Over the course of 18 months almost 200 experts provided their insights and advice. During this webinar we will discuss the main findings of this new, landmark study, and discuss in particular the role that governments and policy makers can play in addressing the high burden that lung cancer presents.

Video & Slides
Webinar: Lung Cancer in Europe: New Ideas for Policy Action2020-09-22T10:41:02+00:00

Webinar: Head & Neck, the cancer you can see…but its impact is unknown to society

8th July, 2020, 08:30 – 09:00 CET

H&N patients haven´t seen innovation in the disease area for the past 10 years. Those patients face stigma and lack of clear pathways to get early treatment. Are we all doing enough to accelerate the process? How do we make others SEE them?

Watch video
Webinar: Head & Neck, the cancer you can see…but its impact is unknown to society2020-07-29T14:01:29+00:00

Webinar: What can Europe learn from Germany’s ‘National Decade Against Cancer’?

17th June 2020, 11.00-12.00 CET

While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?

Watch Video
Webinar: What can Europe learn from Germany’s ‘National Decade Against Cancer’?2020-07-29T14:01:37+00:00

Webinar: Now or later? When is it time to pay for lung cancer screening?

10th June, 2020, 08:30 – 09:00 CET

Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.

Watch Video
Webinar: Now or later? When is it time to pay for lung cancer screening?2020-07-29T14:01:48+00:00
Go to Top